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Abstract. Supercritical or near-critical ﬂuid processes for generating microparticles have enjoyed
considerable attention in the past decade or so, with good success for substances soluble in supercritical
ﬂuids or organic solvents. In this review, we survey their application to the production of protein
particles. A recently developed process known as CO2-assisted nebulization with a Bubble Dryer®
(CAN-BD) has been demonstrated to have broad applicability to small-molecule as well as
macromolecule substances (including therapeutic proteins). The principles of CAN-BD are discussed
as well as the stabilization, micronization and drying of a wide variety of materials. More detailed case
studies are presented for three proteins, two of which are of therapeutic interest: anti-CD4 antibody
(rheumatoid arthritis), α1-antitrypsin (cystic ﬁbrosis and emphysema), and trypsinogen (a model
enzyme). Dry powders were formed in which stability and activity are maintained and which are ﬁne
enough to be inhaled and reach the deep lung. Enhancement of apparent activity after CAN-BD
processing was also observed in some formulation and processing conditions.
KEY WORDS: α1-antitrypsin; anti-CD4 antibody; CAN-BD; CO2-assisted nebulization with a bubble
dryer; trypsinogen.
INTRODUCTION
Preparing protein therapeutics as dry powders is usually
required in order to overcome stability problems that commonly
plague liquid formulations. The most common process for
making dry solid formulations of therapeutic proteins is freeze-
drying, also known as lyophilization (1). Another fairly common
process is spray-drying, especially when the goal is to produce
dry powders of therapeutic proteins and peptides (such as
insulin) for pulmonary delivery (2). In the past decade or so,
several supercritical ﬂuid (SCF) or dense gas processes have
received considerable attention as methods for producing
particles containing a therapeutic agent or agents of interest
that are suitable for pulmonary delivery or controlled release
applications. (“Dense gas” is here deﬁned as a gas in a
supercritical, near-critical or liquid state.) In order for a powder
to be suitable for pulmonary delivery, the aerodynamic size
requirements are that particles must be in the 1 to 5 μm range
(3), but preferably in the 1 to 3 μm range, with optimal size
being ≤2 μm( 4). Production of particles in this size range is
generally possible by applying one of the various SCF
processes, provided that the pharmaceutical is soluble in a
compatible solvent. An elegant and extensive review (albeit
with a disclaimer by the authors that it is not exhaustive) has
earlier been published that surveys the literature and patents
covering the ﬁeld of particle preparation using SCF (5).
Jovanovic et al. (6) have summarized the narrower literature
regarding the stabilization of proteins and drying by SCF
technologies. In their review they discuss effervescent atomiza-
tion, which includes in their terminology CAN-BD and super-
critical assisted atomization (SAA). Shoyele and Cawthorne (7)
have recently reviewed inhaled biopharmaceuticals manufac-
tured by SCF technologies.
In the present review, we survey the application of
various supercritical or near-critical ﬂuid techniques to the
preparation of protein powders and particles, and the
progress to date and the limitations. For proteins and
vaccines, the CO2-assisted nebulization with a Bubble Dry-
er® (CAN-BD) process (8–12) appears to be a very
promising new technology for the preparation of dry ﬁne
powders. This is due to the fact that CAN-BD can nebulize
an aqueous solution without the need to use an organic
solvent. Successful application of CAN-BD to both small-
molecule and protein macromolecule particle preparations is
reviewed. Case studies on the CAN-BD processing of three
proteins, two of which are of clinical therapeutic interest, are
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1972 Cape et al.presented in the ﬁnal sections. Anti-CD4 antibody is a
Primatized® monoclonal antibody that has potential clinical
application in autoimmune and inﬂammatory diseases (13).
Alpha-1-antitrypsin (AAT or α1-AT), also known as α1-
proteinase inhibitor (API or α1-PI), is a serine proteinase
inhibitor in plasma, the primary physiological function of
which is to protect the connective tissue of the lungs from
excessive protease activity by neutrophil elastase (14,15).
AAT has been under clinical investigation (for both intrave-
nous and aerosol pulmonary administration) as a therapeutic
for α1-antitrypsin deﬁciency related emphysema and cystic
ﬁbrosis, diseases in which an imbalance of AAT relative to
elastase is recognized (15,16). Finally, trypsinogen was
selected as a protein model for examining the effects of
formulation conditions and CAN-BD processing on the
biological activity of enzymes.
OVERVIEW OF RAPID EXPANSION
OF SUPERCRITICAL SOLUTIONS (RESS)
The SCF method ﬁrst used for particle preparation is
RESS, rapid expansion of supercritical solutions. As reported
by Jung and Perrut (5), the basic concept of RESS is actually
more than a century old, starting with the work on metal salts
by Hannay and Hogarth (17) in 1879, while the modern
practice and applications to pharmaceuticals have been
developed and patented over the past two decades. Particle
formation by RESS is accomplished by dissolving the
substance of interest in a supercritical ﬂuid and then rapidly
expanding the solution through a nozzle, thereby causing
solute nucleation and particle growth. Successful application
of this process is obviously limited to that category of
substances soluble in a SCF; proteins are not appreciably
soluble in pure carbon dioxide, liquid or supercritical. In fact,
the anti-solvent processes discussed below use supercritical
carbon dioxide (scCO2) to precipitate proteins.
While a variety of supercritical ﬂuids such as pentane,
propane and nitrous oxide have been examined in particle
formation processes, carbon dioxide is overwhelmingly the
ﬂuid of choice, particularly in the anti-solvent methods (5). It
is relatively cheap, has readily accessible critical temperature
(31.1°C) and critical pressure (7.38 MPa or 1,070 psi), has
relatively low toxicity, and is environmentally benign.
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o
r
i
d
e
h
e
t
e
r
o
g
e
n
e
o
u
s
w
i
t
h
P
L
G
A
W
a
t
e
r
/
A
c
e
t
o
n
e
M
e
a
n
=
1
.
3
;
9
5
%
<
2
.
4
;
M
M
A
D
=
2
.
0
μ
m
,
G
S
D
=
1
.
6
P
a
r
t
i
c
l
e
s
p
r
o
d
u
c
e
d
b
y
C
A
N
-
B
D
w
i
t
h
a
c
r
o
s
s
f
r
o
m
a
1
0
%
s
o
d
i
u
m
c
h
l
o
r
i
d
e
s
o
l
u
t
i
o
n
(
w
a
t
e
r
)
a
n
d
a
0
.
5
%
P
L
G
A
s
o
l
u
t
i
o
n
(
a
c
e
t
o
n
e
)
(
9
5
)
S
o
d
i
u
m
c
h
l
o
r
i
d
e
h
e
t
e
r
o
g
e
n
e
o
u
s
w
i
t
h
p
a
l
m
i
t
i
c
a
c
i
d
W
a
t
e
r
/
A
c
e
t
o
n
e
M
e
a
n
=
1
.
5
;
9
5
%
<
2
.
9
;
M
M
A
D
=
2
.
6
μ
m
,
G
S
D
=
1
.
8
P
a
r
t
i
c
l
e
s
p
r
o
d
u
c
e
d
b
y
C
A
N
-
B
D
w
i
t
h
a
c
r
o
s
s
f
r
o
m
a
1
0
%
s
o
d
i
u
m
c
h
l
o
r
i
d
e
s
o
l
u
t
i
o
n
(
w
a
t
e
r
)
a
n
d
a
2
%
p
a
l
m
i
t
i
c
a
c
i
d
s
o
l
u
t
i
o
n
(
a
c
e
t
o
n
e
)
(
9
5
)
S
o
d
i
u
m
c
h
l
o
r
i
d
e
h
e
t
e
r
o
g
e
n
e
o
u
s
w
i
t
h
p
a
l
m
i
t
i
c
a
c
i
d
W
a
t
e
r
/
A
c
e
t
o
n
e
M
e
a
n
=
1
.
5
;
9
5
%
<
3
.
4
;
M
M
A
D
=
3
.
6
μ
m
,
G
S
D
=
1
.
8
P
a
r
t
i
c
l
e
s
p
r
o
d
u
c
e
d
b
y
C
A
N
-
B
D
w
i
t
h
a
c
r
o
s
s
f
r
o
m
a
2
%
s
o
d
i
u
m
c
h
l
o
r
i
d
e
s
o
l
u
t
i
o
n
(
w
a
t
e
r
)
a
n
d
a
2
%
p
a
l
m
i
t
i
c
a
c
i
d
s
o
l
u
t
i
o
n
(
a
c
e
t
o
n
e
)
(
9
5
)
T
e
r
b
u
t
a
l
i
n
e
W
a
t
e
r
N
u
m
b
e
r
d
i
s
t
r
i
b
u
t
i
o
n
:
M
o
d
e
=
0
.
3
–
0
.
7
;
V
o
l
u
m
e
d
i
s
t
r
i
b
u
t
i
o
n
:
m
e
a
n
=
0
.
7
–
2
.
6
;
1
0
0
%
<
4
.
0
P
a
r
t
i
c
l
e
s
i
z
e
d
i
s
t
r
i
b
u
t
i
o
n
d
e
t
e
r
m
i
n
e
d
f
r
o
m
a
s
t
a
t
i
s
t
i
c
a
l
a
n
a
l
y
s
i
s
o
f
∼
1
,
0
0
0
p
a
r
t
i
c
l
e
s
i
n
s
c
a
n
n
i
n
g
e
l
e
c
t
r
o
n
m
i
c
r
o
g
r
a
p
h
s
(
1
1
5
)
T
e
t
r
a
c
y
c
l
i
n
e
W
a
t
e
r
N
u
m
b
e
r
d
i
s
t
r
i
b
u
t
i
o
n
:
m
o
d
e
=
0
.
3
–
0
.
5
;
v
o
l
u
m
e
d
i
s
t
r
i
b
u
t
i
o
n
:
m
e
a
n
=
0
.
5
–
1
.
2
;
1
0
0
%
<
2
.
4
P
a
r
t
i
c
l
e
s
i
z
e
d
i
s
t
r
i
b
u
t
i
o
n
d
e
t
e
r
m
i
n
e
d
f
r
o
m
a
s
t
a
t
i
s
t
i
c
a
l
a
n
a
l
y
s
i
s
o
f
∼
1
,
0
0
0
p
a
r
t
i
c
l
e
s
i
n
s
c
a
n
n
i
n
g
e
l
e
c
t
r
o
n
m
i
c
r
o
g
r
a
p
h
s
(
1
0
3
,
1
1
4
)
T
o
b
r
a
m
y
c
i
n
s
u
l
f
a
t
e
W
a
t
e
r
0
.
5
–
3
.
2
(
1
0
0
,
1
1
6
)
T
r
i
c
l
a
b
e
n
z
a
d
o
l
M
e
t
h
a
n
o
l
1
–
2
I
r
r
e
g
u
l
a
r
c
r
y
s
t
a
l
s
(
8
6
)
Y
t
t
r
i
u
m
a
c
e
t
a
t
e
W
a
t
e
r
<
0
.
2
5
–
3
.
5
A
m
o
r
p
h
o
u
s
s
p
h
e
r
i
c
a
l
p
a
r
t
i
c
l
e
s
(
8
6
,
1
0
3
)
Y
t
t
r
i
u
m
a
c
e
t
a
t
e
M
e
t
h
a
n
o
l
<
0
.
1
–
1
.
0
A
m
o
r
p
h
o
u
s
s
p
h
e
r
i
c
a
l
p
a
r
t
i
c
l
e
s
(
8
6
,
1
0
3
)
Z
a
n
a
m
i
v
i
r
(
R
e
l
e
n
z
a
®
)
W
a
t
e
r
R
e
s
p
.
f
r
a
c
t
i
o
n
=
7
3
%
<
5
μ
m
;
(
M
M
A
D
=
2
.
4
μ
m
)
(
6
9
,
7
0
,
1
0
1
)
Z
i
n
c
a
c
e
t
a
t
e
M
e
t
h
a
n
o
l
<
0
.
5
A
m
o
r
p
h
o
u
s
s
p
h
e
r
i
c
a
l
p
a
r
t
i
c
l
e
s
(
8
6
)
Z
i
r
c
o
n
y
l
n
i
t
r
a
t
e
h
y
d
r
a
t
e
W
a
t
e
r
1
.
5
–
3
A
m
o
r
p
h
o
u
s
s
p
h
e
r
i
c
a
l
p
a
r
t
i
c
l
e
s
(
8
6
)
T
a
b
l
e
I
I
.
(
c
o
n
t
i
n
u
e
d
)
S
u
b
s
t
a
n
c
e
S
o
l
v
e
n
t
P
a
r
t
i
c
l
e
S
i
z
e
s
(
m
m
)
M
i
s
c
e
l
l
a
n
e
o
u
s
R
e
s
u
l
t
s
o
r
N
o
t
e
s
R
e
f
e
r
e
n
c
e
s
S
u
b
s
t
a
n
c
e
S
o
l
v
e
n
t
P
a
r
t
i
c
l
e
S
i
z
e
s
(
µ
m
)
M
i
s
c
e
l
l
a
n
e
o
u
s
R
e
s
u
l
t
s
o
r
N
o
t
e
s
R
e
f
e
r
e
n
c
e
s
1976 Cape et al.T
a
b
l
e
I
I
I
.
S
u
m
m
a
r
y
o
f
P
a
r
t
i
c
l
e
s
P
r
o
d
u
c
e
d
b
y
C
A
N
-
B
D
C
o
n
t
a
i
n
i
n
g
P
r
o
t
e
i
n
s
o
r
o
t
h
e
r
B
i
o
l
o
g
i
c
a
l
s
P
r
o
t
e
i
n
S
o
l
v
e
n
t
P
a
r
t
i
c
l
e
S
i
z
e
s
(
μ
m
)
B
i
o
l
o
g
i
c
a
l
A
c
t
i
v
i
t
y
M
i
s
c
e
l
l
a
n
e
o
u
s
R
e
s
u
l
t
s
o
r
N
o
t
e
s
R
e
f
e
r
e
n
c
e
s
A
l
p
h
a
-
1
-
a
n
t
i
t
r
y
p
s
i
n
W
a
t
e
r
M
e
a
n
=
1
.
9
–
2
.
2
(
9
5
%
<
5
.
3
–
5
.
4
)
F
u
l
l
r
e
t
e
n
t
i
o
n
o
f
e
n
z
y
m
a
t
i
c
a
c
t
i
v
i
t
y
.
F
o
r
m
u
l
a
t
e
d
i
n
b
u
f
f
e
r
e
d
s
o
l
u
t
i
o
n
w
i
t
h
t
r
e
h
a
l
o
s
e
a
n
d
T
w
e
e
n
2
0
a
s
s
t
a
b
i
l
i
z
i
n
g
e
x
c
i
p
i
e
n
t
s
T
h
i
s
w
o
r
k
A
n
t
i
-
C
D
4
W
a
t
e
r
M
e
a
n
=
1
.
4
–
1
.
8
(
9
5
%
<
3
.
5
–
5
.
5
)
F
u
l
l
r
e
t
e
n
t
i
o
n
o
f
a
n
t
i
g
e
n
b
i
n
d
i
n
g
a
c
t
i
v
i
t
y
.
F
o
r
m
u
l
a
t
e
d
i
n
b
u
f
f
e
r
e
d
s
o
l
u
t
i
o
n
w
i
t
h
s
a
c
c
h
a
r
i
d
e
a
n
d
s
u
r
f
a
c
t
a
n
t
a
s
s
t
a
b
i
l
i
z
i
n
g
e
x
c
i
p
i
e
n
t
s
T
h
i
s
w
o
r
k
H
e
p
a
t
i
t
i
s
B
s
u
r
f
a
c
e
a
n
t
i
g
e
n
p
r
o
t
e
i
n
(
H
B
s
A
g
)
,
a
l
u
m
i
n
u
m
h
y
d
r
o
x
i
d
e
a
d
j
u
v
a
n
t
e
d
W
a
t
e
r
N
o
t
r
e
p
o
r
t
e
d
F
u
l
l
r
e
t
e
n
t
i
o
n
o
f
i
n
v
i
t
r
o
(
E
L
I
S
A
)
a
c
t
i
v
i
t
y
e
v
e
n
a
f
t
e
r
s
t
o
r
a
g
e
a
t
−
2
0
°
C
o
r
6
6
°
C
f
o
r
4
3
d
a
y
s
.
F
u
l
l
r
e
t
e
n
t
i
o
n
o
f
i
m
m
u
n
o
g
e
n
i
c
i
t
y
i
n
m
i
c
e
a
f
t
e
r
p
r
o
c
e
s
s
i
n
g
F
o
r
m
u
l
a
t
e
d
w
i
t
h
t
r
e
h
a
l
o
s
e
o
r
t
r
e
h
a
l
o
s
e
p
l
u
s
p
o
l
y
v
i
n
y
l
p
y
r
r
o
l
i
d
o
n
e
(
P
V
P
)
(
6
9
,
7
0
)
I
g
G
(
h
u
m
a
n
)
W
a
t
e
r
R
e
s
p
.
f
r
a
c
t
i
o
n
=
9
4
%
<
5
μ
m
F
u
l
l
p
r
e
s
e
r
v
a
t
i
o
n
o
f
t
o
t
a
l
h
u
m
a
n
I
g
G
c
o
n
t
e
n
t
a
n
d
f
u
l
l
r
e
t
e
n
t
i
o
n
o
f
a
c
t
i
v
i
t
y
a
g
a
i
n
s
t
i
n
ﬂ
u
e
n
z
a
A
a
s
m
e
a
s
u
r
e
d
b
y
E
L
I
S
A
a
s
s
a
y
s
F
o
r
m
u
l
a
t
e
d
a
s
t
h
e
c
o
m
m
e
r
c
i
a
l
P
o
l
y
g
a
m
®
S
/
D
I
m
m
u
n
e
G
l
o
b
u
l
i
n
I
n
t
r
a
v
e
n
o
u
s
,
a
l
y
o
p
h
i
l
i
z
e
d
f
o
r
m
u
l
a
t
i
o
n
c
o
n
t
a
i
n
i
n
g
s
o
d
i
u
m
c
h
l
o
r
i
d
e
,
h
u
m
a
n
a
l
b
u
m
i
n
,
g
l
y
c
i
n
e
,
g
l
u
c
o
s
e
,
p
o
l
y
e
t
h
y
l
e
n
e
g
l
y
c
o
l
,
a
n
d
o
t
h
e
r
t
r
a
c
e
c
o
m
p
o
n
e
n
t
s
(
1
0
1
,
1
0
5
)
L
a
c
t
a
t
e
d
e
h
y
d
r
o
g
e
n
a
s
e
W
a
t
e
r
1
–
3
1
5
%
o
f
o
r
i
g
i
n
a
l
a
c
t
i
v
i
t
y
(
n
o
s
t
a
b
i
l
i
z
i
n
g
e
x
c
i
p
i
e
n
t
s
a
d
d
e
d
)
;
4
0
%
t
o
>
9
5
%
o
f
o
r
i
g
i
n
a
l
a
c
t
i
v
i
t
y
d
e
p
e
n
d
i
n
g
o
n
s
t
a
b
i
l
i
z
i
n
g
e
x
c
i
p
i
e
n
t
s
a
d
d
e
d
(
9
1
,
9
2
)
L
a
c
t
a
t
e
d
e
h
y
d
r
o
g
e
n
a
s
e
W
a
t
e
r
0
.
5
–
5
(
m
e
a
n
=
∼
3
)
F
u
l
l
r
e
t
e
n
t
i
o
n
a
n
d
e
v
e
n
e
n
h
a
n
c
e
m
e
n
t
o
f
o
r
i
g
i
n
a
l
a
c
t
i
v
i
t
y
p
o
s
s
i
b
l
e
V
a
r
i
o
u
s
s
t
a
b
i
l
i
z
i
n
g
e
x
c
i
p
i
e
n
t
s
(
t
y
p
e
a
n
d
a
m
o
u
n
t
)
t
e
s
t
e
d
(
1
1
,
1
1
7
)
L
y
s
o
z
y
m
e
W
a
t
e
r
1
–
3
>
9
0
%
o
f
o
r
i
g
i
n
a
l
a
c
t
i
v
i
t
y
r
e
t
a
i
n
e
d
r
e
g
a
r
d
l
e
s
s
o
f
a
d
d
i
t
i
o
n
o
r
n
o
t
o
f
s
t
a
b
i
l
i
z
i
n
g
e
x
c
i
p
i
e
n
t
s
(
d
i
s
a
c
c
h
a
r
i
d
e
a
n
d
/
o
r
s
u
r
f
a
c
t
a
n
t
)
(
9
1
,
9
2
)
M
e
a
s
l
e
s
v
a
c
c
i
n
e
v
i
r
u
s
,
l
i
v
e
-
a
t
t
e
n
u
a
t
e
d
W
a
t
e
r
R
e
s
p
.
f
r
a
c
t
i
o
n
=
9
4
%
<
5
μ
m
;
(
M
M
A
D
=
1
.
9
μ
m
)
F
u
l
l
r
e
t
e
n
t
i
o
n
o
f
v
i
r
u
s
a
c
t
i
v
i
t
y
a
s
m
e
a
s
u
r
e
d
b
y
a
s
t
a
n
d
a
r
d
p
l
a
q
u
e
a
s
s
a
y
T
r
e
h
a
l
o
s
e
w
a
s
a
d
d
e
d
t
o
a
c
o
m
m
e
r
c
i
a
l
l
y
o
p
h
i
l
i
z
e
d
m
e
a
s
l
e
s
v
a
c
c
i
n
e
f
o
r
m
u
l
a
t
i
o
n
f
o
r
p
r
o
c
e
s
s
i
n
g
.
P
a
r
t
i
c
l
e
s
i
z
i
n
g
w
a
s
c
o
n
d
u
c
t
e
d
o
n
a
c
o
r
r
e
s
p
o
n
d
i
n
g
v
i
r
u
s
-
f
r
e
e
p
l
a
c
e
b
o
f
o
r
m
u
l
a
t
i
o
n
(
6
9
,
7
0
)
M
e
a
s
l
e
s
v
a
c
c
i
n
e
v
i
r
u
s
,
l
i
v
e
-
a
t
t
e
n
u
a
t
e
d
W
a
t
e
r
R
e
s
p
.
m
a
s
s
f
r
a
c
t
i
o
n
=
4
2
%
t
o
5
0
%
<
5
.
8
μ
m
,
1
7
%
t
o
3
0
%
<
3
.
3
µ
m
5
0
%
t
o
8
0
%
o
f
o
r
i
g
i
n
a
l
a
c
t
i
v
i
t
y
a
s
m
e
a
s
u
r
e
d
b
y
a
s
t
a
n
d
a
r
d
p
l
a
q
u
e
a
s
s
a
y
.
L
e
s
s
t
h
a
n
1
l
o
g
l
o
s
s
i
n
v
i
r
a
l
a
c
t
i
v
i
t
y
o
f
t
h
e
p
o
w
d
e
r
a
f
t
e
r
7
d
a
y
s
a
t
3
7
°
C
T
h
e
v
a
c
c
i
n
e
v
i
r
u
s
w
a
s
f
o
r
m
u
l
a
t
e
d
w
i
t
h
m
y
o
-
i
n
o
s
i
t
o
l
a
s
t
h
e
p
r
i
m
a
r
y
s
t
a
b
i
l
i
z
i
n
g
e
x
c
i
p
i
e
n
t
.
O
t
h
e
r
s
t
a
b
i
l
i
z
e
r
s
i
n
c
l
u
d
e
d
h
y
d
r
o
l
y
z
e
d
g
e
l
a
t
i
n
,
a
m
i
n
o
a
c
i
d
s
,
a
n
d
a
b
u
f
f
e
r
(
7
1
–
7
5
)
O
v
a
l
b
u
m
i
n
W
a
t
e
r
0
.
3
–
5
N
o
t
d
e
t
e
r
m
i
n
e
d
O
r
i
g
i
n
a
l
a
q
u
e
o
u
s
s
o
l
u
t
i
o
n
c
o
n
t
a
i
n
e
d
5
%
o
v
a
l
b
u
m
i
n
a
n
d
5
%
t
r
e
h
a
l
o
s
e
(
8
,
9
2
,
9
4
)
O
v
a
l
b
u
m
i
n
,
w
i
t
h
D
P
P
C
a
n
d
l
a
c
t
o
s
e
E
t
h
a
n
o
l
/
w
a
t
e
r
(
8
0
:
2
0
)
M
e
a
n
=
0
.
5
6
(
9
5
%
<
0
.
9
6
)
N
o
t
d
e
t
e
r
m
i
n
e
d
P
a
r
t
i
c
l
e
s
p
r
o
d
u
c
e
d
f
r
o
m
a
n
e
t
h
a
n
o
l
/
w
a
t
e
r
s
o
l
u
t
i
o
n
(
8
0
:
2
0
v
o
l
u
m
e
r
a
t
i
o
)
c
o
n
t
a
i
n
i
n
g
0
.
0
6
%
D
P
P
C
,
0
.
0
2
%
l
a
c
t
o
s
e
,
a
n
d
0
.
0
2
%
c
h
i
c
k
e
n
e
g
g
a
l
b
u
m
i
n
(
1
0
5
)
S
m
a
l
l
p
e
p
t
i
d
e
n
e
w
d
r
u
g
e
n
t
i
t
y
E
t
h
a
n
o
l
M
e
a
n
=
0
.
9
3
(
9
5
%
<
1
.
8
)
N
o
t
r
e
p
o
r
t
e
d
L
o
w
d
e
n
s
i
t
y
p
a
r
t
i
c
l
e
s
w
i
t
h
m
u
c
h
l
a
r
g
e
r
g
e
o
m
e
t
r
i
c
d
i
a
m
e
t
e
r
s
(
∼
4
μ
m
)
o
b
s
e
r
v
e
d
b
y
S
E
M
(
1
0
6
)
T
r
y
p
s
i
n
o
g
e
n
W
a
t
e
r
0
.
5
–
7
(
m
e
a
n
=
∼
3
)
F
u
l
l
r
e
t
e
n
t
i
o
n
a
n
d
e
v
e
n
e
n
h
a
n
c
e
m
e
n
t
o
f
o
r
i
g
i
n
a
l
a
c
t
i
v
i
t
y
p
o
s
s
i
b
l
e
V
a
r
i
o
u
s
s
t
a
b
i
l
i
z
i
n
g
e
x
c
i
p
i
e
n
t
s
(
t
y
p
e
a
n
d
a
m
o
u
n
t
)
t
e
s
t
e
d
(
1
1
7
)
R
e
f
e
r
e
n
c
e
1977 Preparation of Active Proteins, Vaccines and PharmaceuticalsOVERVIEW OF DENSE GAS ANTI-SOLVENT
PROCESSES
While RESS is not applicable to the formation of protein
particles, processes that take advantage of the ability of
supercritical ﬂuids or compressed gases to precipitate pro-
teins have been investigated for this purpose. These processes
all work on the same principle: the dense gas acts as an anti-
solvent when it dissolves in and expands a solvent containing
the target solute(s), causing supersaturation and precipitation
of the solute(s) in a high pressure chamber, usually operating
at pressures >1,200 psi. The solvent and supercritical or near-
critical ﬂuid must be miscible. Unfortunately, the preferred
solvent for most proteins, water, is very poorly miscible with
dense CO2: at 21°C and 1,200 psi, only ∼0.3 mole% of water
dissolves in CO2 and only ∼2.5 mole% of CO2 dissolves in
water (18). Therefore, the application of dense gas anti-
solvent processes is largely restricted to pharmaceuticals
(such as lipophilic compounds) dissolvable in organic solvents
that are miscible with the dense gas. Although the basic
principle is the same in several processes, the various speciﬁc
implementations of this principle have acquired different
names and acronyms in the literature.
Gas anti-solvent (GAS) precipitation and Supercritical
ﬂuid anti-solvent (SAS) precipitation are essentially synony-
mous and refer speciﬁcally to the batch expansion of a solute-
containing solvent by a dense gas. Aerosol solvent extraction
system (ASES) is a modiﬁcation of GAS/SAS in which the
solute-containing solvent is sprayed through an atomization
nozzle into the compressed anti-solvent. Precipitation from
compressed anti-solvent (PCA) is another designation found in
the literature for what is essentially the ASES process. Solution
enhanced dispersion by supercritical ﬂuids (SEDS) is a
reﬁnement and modiﬁcation of ASES in which a special nozzle
with two (or three) coaxial channels is used to combine the
SCF with the other solvents and spray the mixture into the
same SCF. The three-channel nozzle allows aqueous solutions
to be processed by SEDS by using an organic solvent, such as
ethanol, that is miscible in both the aqueous solution and
scCO2, to promote miscibility between scCO2 and water.
Anti-solvent processes have been applied to the prepa-
ration of protein particles with only limited success. Success is
deﬁned here as the formation of ﬁne protein particles with
mean aerodynamic diameter of less than 5 μm and essentially
full retention of biological activity. Table I summarizes the
various proteins that have been processed into particles using
anti-solvent methods. Particles of hydrophobic proteins such
as insulin or generally robust proteins such as lysozyme that
tolerate dissolution in or contact with organic solvents have
been successfully prepared using GAS/SAS or related
methods. Essentially full retention of activity has repeatedly
been possible with lysozyme and insulin, which are relatively
robust when compared with other proteins and peptides. For
example, both of these proteins can be dried without
stabilizing excipients and fully recover native structure and
function after rehydration (19–21). In contrast, more labile
proteins such as lactate dehydrogenase or Factor XIII are
irreversibly denatured if they are subjected to drying without
stabilizers (22–24). Success in stabilization and micronization
is generally much more limited for other proteins and
peptides. The literature review presented in Table I demon-
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1978 Cape et al.strates that in the overwhelming majority of attempts to
produce protein particles by anti-solvent techniques, post-
processing biological activity was either low or not deter-
mined or not reported.
Lysozyme is often chosen as a model protein for proof of
concept testing of new techniques or processes because it is
robust and is arguably the most investigated protein of all
time for processing, formulation and drug delivery systems.
This holds true in the developmental history of anti-solvent
processes. Lysozyme is a good model to start with, but success
with it far from guarantees success with any other protein,
especially more labile ones. Before general claims of applica-
bility to protein processing are made, a number of proteins
should be tested, particularly ones that might be sensitive to
stresses (such as organic solvent exposure and dehydration)
encountered in the process.
It is well established in the published literature [see
reviews by Carpenter et al. (60) and Wang (1)] that successful
preparation of proteins in a dry solid form by lyophilization
generally requires the addition of stabilizing excipients such
as disaccharides (e.g., sucrose or trehalose) and/or surfactants
(e.g., Tween 20 or 80). Careful pre-formulation studies are
often undertaken in order to identify the optimal formulation:
buffer type, amount, and pH; disaccharide type and amount;
surfactant type and amount; etc. The dense gas anti-solvent
processes discussed here do not lend themselves to such
careful formulation endeavors. Differential precipitation of
the various excipients during expansion by the dense gas
would complicate the formulation efforts. Carpenter et al.
(60) make a strong case that long-term storage stability of
proteins in a dry solid form generally hinges on whether or
not native protein secondary structure is retained. In most of
the cases in Table I, protein secondary structure was not
considered nor investigated. Winters et al. (45) did examine
secondary structure and found that there was minimal
secondary structure perturbation in the dry solid due to
ASES processing in the case of lysozyme, but moderate and
appreciable perturbation in the cases of trypsin and insulin,
respectively. Protein contact with or dissolution in the organic
solvent(s) required for anti-solvent processing will usually
signiﬁcantly complicate the attempts to maintain native
secondary structure, since such solvents are often protein
denaturants. With a few exceptions, those investigators that
did determine biological activity after processing did not,
however, determine the long-term stability of the protein
subjected to anti-solvent processing. Winters et al. (46)
observed that the activity and secondary structure of lyso-
zyme, trypsin and insulin in particles produced by ASES were
maintained upon long-term storage at various temperatures
relative to the activity and secondary structure determined
immediately after processing (45). Thiering et al. (42,44),
however, observed a 25% to 50% reduction in lysozyme
activity upon storage over 3 months at 20°C of lysozyme
particles produced by GAS. Despite the success by Winters et
al. (45,46), given the relatively poor track record or lack of
data for proteins to date, particularly for proteins other than
lysozyme, insulin and trypsin, one should not expect that
dense gas anti-solvent processes will be broadly applicable to
preparations of particles of stable protein formulations. The
instability of many proteins and enzymes in contact with
organic solvents (61) should lead one to conclude that
processes requiring organic solvents will only be useful for a
limited number of these biomolecules.
A few approaches to protein particle formation have
involved dense gas processing of solid protein cakes or
suspensions. Castor and Hong (62) obtained a patent for a
process in which solid protein (e.g., from a lyophilized cake)
is contacted with a supercritical ﬂuid and then rapidly
depressurized to achieve size reduction. Resulting size
distributions were usually very broad with sizes typically
ranging from tens of microns to several hundred microns.
Although it was stated in the patent that retention of full
activity was expected, no supporting activity data was
presented. Young et al. (63) used a variation of ASES to
encapsulate lysozyme in polymer microspheres. Lysozyme,
spray-dried from aqueous solution to form 1–10 μm particles,
was suspended in a solution of poly(lactic acid) (PLA) or poly
(lactic acid-co-glycolic acid) (PGLA) in dichloromethane and
then sprayed through a nozzle into a CO2 vapor phase over a
CO2 liquid phase, leading to precipitation of the polymer and
encapsulation of the lysozyme. Particle sizes were typically 5
to 60 μm. The biological activity of the processed lysozyme
was not reported. Mishima et al. (64) used a variation of
RESS to encapsulate lysozyme and lipase into various
polymers. Solid protein was suspended in scCO2 containing
a cosolvent (e.g., ethanol) and dissolved polymer (e.g.,
polyethylene glycol (PEG)) and then rapidly expanded
through a capillary nozzle to atmospheric conditions. Particles
containing encapsulated protein with primary diameters
ranging from 8 to 62 μm were reported. No biological activity
data were reported. In more recent reports (65–68), dry
particles (produced by milling and sieving of lyophilized
material) or dry microcrystals of several proteins and
enzymes have been coated or encapsulated using SCF
processes; full or very good retention of activity was reported
for these proteins.
CO2-ASSISTED NEBULIZATION WITH A BUBBLE
DRYER® (CAN-BD)
CAN-BD is a process patented by Sievers et al. (8–12).
This invention covers two versions of the process, static and
dynamic. The static version involves the pre-mixing of scCO2
and a solution containing a solute of interest at a pressure
higher than the critical pressure of CO2. After equilibrium is
established or approached, the mixture in a high pressure
chamber is allowed to expand to atmospheric pressure
through a ﬂow restrictor (or a capillary tube) by expansion
into a drying chamber.
The dynamic version involves continuous intimate mix-
ing of a solution containing a solute of interest and scCO2 or
near-critical CO2. In one version of this process, the two ﬂuid
streams become intimately mixed in a low dead volume tee
and are then expanded through a ﬂow restrictor to atmo-
spheric pressure, where the plume of microbubbles and
microdroplets are rapidly dried. This dynamic version of
CAN-BD has been consistently, repeatedly and broadly
successful in preparing protein particles that are usually
stable, active and in the size range suitable for pulmonary
delivery. This success has been achieved because the aqueous
solution or suspension containing a protein or vaccine virus
can be formulated to contain the appropriate stabilizers.
1979 Preparation of Active Proteins, Vaccines and PharmaceuticalsRecently, the CAN-BD process has been used to produce dry
powders of live-attenuated measles vaccine virus (Edmonston-
Zagreb) with good mechanical yield and with retention of viral
activity as measured by a plaque forming unit assay that is
comparable to commercial lyophilization (69–75). CAN-BD
has also been used to dry siRNA nucleotides (71). Depending
on formulation and laboratory processing conditions, typical
lab scale yields range between 50% and 90%. In traditional
spray drying, yield usually increases with scale, and the same
may be realized for CAN-BD, in which droplet drying and
particle collection is similar to traditional spray drying.
In papers by Abdul-Fattah et al. (76,77) and patent
applications by Truong-Le et al. (78–81), drying process
methods are described that are similar to the CAN-BD
process patents (8–12). Truong-Le et al. called this process,
which uses compressed ﬂuids of carbon dioxide, nitrogen,
helium, or argon, “high pressure effervescent atomization” or
“high pressure spray drying”. Both carbon dioxide and
nitrogen were used at similar temperatures and pressures in
the 1997 patent (8). In some of the examples given by
Truong-Le et al. (78–81), particles of stable live attenuated B/
Harbin inﬂuenza virus can be stored with only about one log
loss of activity over one year at 25°C. High pressure spray
drying was also used to prepare dry powders of an IgG
monoclonal antibody and a live attenuated virus vaccine of a
parainﬂuenza strain (76,77). The spray dried vaccine prepa-
ration was less stable compared to that from foam drying but
more stable than that obtained by freeze drying. Additionally,
in a recently issued patent by Shekunov et al. (82) and in
patent applications by Truong-Le et al. (83,84), spray freeze
drying methods are described that employ the nebulization
method patented earlier (8,9,11), combined with a freeze
drying or lyophilization step. Shekunov et al. (82,85) showed
that >80% of the biological activity of trypsinogen (formu-
lated with trehalose) could be retained using their modiﬁca-
tion of the CAN-BD process. B/Harbin inﬂuenza virus
processed with the Truong-Le et al. (83,84) spray freeze
drying method was reported to have only lost about one log
Fig. 2. SEM image of particles of anti-CD4 antibody produced by
CAN-BD at 50°C (Run A). SEM images obtained as described
elsewhere (91).
Fig. 4. TEM image of particles of anti-CD4 antibody produced by
CAN-BD at 50°C (Run A). Particles were physically adhered to
glow-discharged, carbon-coated, Formvar-coated copper grids by
gently touching the activated side of the grid to the powder and then
were visualized using a Philips CM 10 microscope operated at an
accelerating voltage of 80 kV.
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Fig. 5. Aerodynamic size distribution of particles of anti-CD4
antibody produced by CAN-BD at 50°C (Run A). Mean size=
1.4 μm with 95% of the particles less than 3.5 μm. Size distributions
for the case studies presented in this manuscript were weighted by
number. Particle sizes were measured using a TSI Model 3225
Aerosizer® DSP, which employs a laser-detected time of ﬂight
technique.
Fig. 3. SEM image of particles of anti-CD4 antibody produced by
CAN-BD at about 30°C (Run B). CAN-BD at about 30°C (Run B).
1980 Cape et al.of activity over 13 months at 25°C or 67 days at 37°C for
certain formulations. One variant of the CAN-BD process
has also been referred to by Reverchon et al. (86–88)a s
supercritical-assisted atomization (SAA) in the published
literature. In SAA, carbon dioxide is intimately mixed with
the solution to be dried in a large high pressure chamber
containing packing that provides a large surface area, to
achieve effervescent atomization.
Principles of CAN-BD
Unlike the anti-solvent processes, CAN-BD does not
employ dense gases to achieve precipitation by solubility
reduction of the solute(s) to be micronized. Rather they are
used to enhance or facilitate the nebulization or aerosoliza-
tion of a liquid solution, which is then rapidly dried to form
particles by solvent removal. Organic or aqueous solutions
are both readily processed by CAN-BD, although neither
solvent type needs to be present for the processing of the
other. CAN-BD is broadly applicable to the processing of
aqueous protein solutions and therefore lends itself readily to
studies undertaken to create dry solid formulations optimized
for protein storage stability and retention of biological
activity, and to develop such protein particles with morphol-
ogy and size suitable for pulmonary administration.
The principles of the CAN-BD process and the experi-
mental setup have been previously described elsewhere (89–
95). They are here brieﬂy described again. Figure 1 is a
schematic diagram of a typical CAN-BD system. A liquid
solution (organic or aqueous), typically containing 1% to
10% total dissolved solids, is brought into intimate contact
with supercritical or near-critical CO2 (usually at 1,200 to
1,500 psi and 20°C to 35°C, although a wide variety of
conditions can be used) in a low dead volume tee. The
resulting emulsion or solution mixture is rapidly expanded to
near atmospheric pressure through a capillary ﬂow restrictor,
which is usually fused silica, stainless steel or PEEK with an
inner diameter of 50 to 175 μm and a length of ∼10 cm. Upon
expansion, the emulsion or solution forms a dense aerosol
consisting of microdroplets and microbubbles. The aerosol is
formed primarily due to the sudden physical dispersion of the
liquid solution caused by the rapid expansion of compressed
CO2. Further break up of the microdroplets occurs due to the
sudden release of any CO2 that became dissolved in the liquid
solution during intimate contact in the tee. At 1,000 to
2,000 psi, the solubility of CO2 in water is about 2 to 2.5 mole
%( 18). The dense aerosol is delivered into a drying chamber
(maintained at or near atmospheric pressure), into which pre-
heated air or nitrogen gas is also delivered so as to maintain
the chamber at a desired average drying temperature
(typically 25°C to 65°C when processing aqueous protein
solutions). Drying of an aerosol droplet is very fast. Adler
and Lee (96) calculated that the total drying time in a Buchi
spray-dryer (Tinlet=150°C, Toutlet=95°C) was less than 2 ms
for a 8.6 μm droplet containing 10% (w/w) trehalose. In
CAN-BD, the average residence time of a droplet/dry particle
in the drying chamber has been estimated from chamber
volume and ﬂow rate calculations to be a few seconds (94). It
should be noted that the droplet drying time will be shorter
than the residence time. Microbubbles should dry even faster
than microdroplets with the same diameter.
In drying some substances by CAN-BD, hollow dry
particles are formed. Dry particles are collected on a ﬁlter
membrane, with pore sizes between 0.2 and 0.45 μm, located
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Fig. 6. Size-exclusion chromatograms of rehydrated dry powders of
anti-CD4 antibody produced by CAN-BD at 50°C (Run A)
compared to the starting material. Numbers above or next to peaks
refer to their area percents. Size-exclusion HPLC was performed
using an HPLC system (Agilent Technology 1100 series) equipped
with a TSK-Gel G3000SWXL column (Tosoh Biosep LLC, Pennsyl-
vania, USA), using a phosphate based buffer for elution.
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Fig. 7. Second-derivative infrared spectroscopy of unprocessed bulk
solution and powders of anti-CD4 antibody produced by CAN-BD at
30°C (Run B) and 50°C (Run A). IR spectra were collected and
analyzed according to the methods described by Dong et al. (119–121).
Table IV. Percentage of Binding Activity of Anti-CD4 Antibody to
its Antigen as Measured by a Standard ELISA Method
Sample description % binding activity±SD
Bulk solution 106±6
CAN-BD 91±10
Lyophilized 95±7
A goat anti-human IgG HRP conjugate and ABTS were used to
detect the bound antibodies on the soluble CD4 antigen-coated plate
1981 Preparation of Active Proteins, Vaccines and Pharmaceuticalsat the outlet of the drying chamber. CAN-BD can be
operated as either a batch, semi-continuous, or continuous
process. Typical ﬂow rates on a lab-scale are 0.3 to 0.6 ml/min
of liquid solution and 1 to 3 ml/min of dense CO2. We have
successfully scaled up CAN-BD to process up to 20 ml/min of
liquid solution (97), and have more recently used ﬂow rates
as high as 30 ml/min, which is commercial production scale
for high value pharmaceutical products (98).
Organic solvents that are compatible with liquid carbon
dioxide can be substituted in part or totally for water.
Examples that the authors have used include ethanol,
methanol, acetone, ethyl acetate and various mixtures of
solvents, surfactants, buffers, stabilizers and other excipients.
The solvent choice depends on the solubility and stability of
the pharmaceutical to be micronized, and on the desired
morphology and mean size of the particles.
Review of Successful Applications of CAN-BD
Application of the CAN-BD process to produce ﬁne
particles of a variety of substances dissolved in a variety of
solvents has been broadly successful. Table II summarizes the
application of CAN-BD to small-molecule substances such as
salts, sugars and low-molecular weight pharmaceutical prod-
ucts. Particles in the respirable size range of 1 to 5 μm were
consistently produced. The CAN-BD process has also been
applied to the preparation of protein particles with broad
success. Table III summarizes the examples of CAN-BD in
protein processing to form stable active powders. To achieve
the desired protein stability and retention of biological
activity, addition of pH buffers and appropriate stabilizing
excipients such as disaccharide sugars (e.g., sucrose or
trehalose) or surfactants (e.g., Tween 20 or Tween 80) are
usually required. However, addition of these solution compo-
nents does not pose any extra processing difﬁculties for CAN-
BD. Full retention of biological activity is readily and
repeatedly observed for proteins appropriately formulated.
An interesting example of a protein vaccine that has shown
full retention of activity after CAN-BD processing, as
indicated in both in vitro (ELISA) and in vivo (mice) tests,
is the hepatitis B surface antigen (HBsAg) (69,70). As
mentioned above, CAN-BD has been recently used to
prepare ﬁne dry powders of live attenuated measles vaccine
virus (69–75). For a myo-inositol based formulation under
development as an inhalable dry powder vaccine, it was
determined that 72%±18% SD (n=8) of the viral activity was
preserved through CAN-BD processing (74,75). This com-
pares favorably with freeze drying of the commercial sorbitol
based measles vaccine formulation, in which retention of
activity is on the order of 50% to 60%. In addition, the
CAN-BD prepared powder formulation passed the World
Health Organization stability criterion of less than one log
loss (or less than 90% loss) after 7 days of storage at 37°C.
Speciﬁcally, the myo-inositol based formulation retained
20%±9% SD (n=4) of the viral activity after 7 days at
37°C. Aerodynamic diameters by cascade impaction were
determined to be 45% to 50%<5.8 μm and ∼20%<3.3 μm. In
vivo viral replication was demonstrated by the observation by
polymerase chain reaction (PCR) assay of measles vaccine
virus nucleoproteins in the lungs of Cotton rats 7 to 14 days
after the rats were allowed to inhale an aerosolized powder of
the myo-inositol based CAN-BD powder formulation (75).
Under certain formulation conditions, apparent enhance-
ment of the enzymatic activity of lactate dehydrogenase
(LDH) and trypsinogen has been observed (11,117). This
indicates that treatment with supercritical or near-critical CO2
can possibly refold the protein molecules in the original stock
solution that are denatured or in a subactive folded confor-
mation to a native and active structure. Independent inves-
tigators have reported similar results. Giessauf and Gamse
(118) reported increases in the enzymatic activity of porcine
Fig. 8. SEM image of AAT particles produced by CAN-BD at 40°C
from an aqueous solution containing AAT and trehalose (3 to 5 mass
ratio) in 0.1 M sodium phosphate, pH 7.0 buffer with 0.1% Tween 20.
Table V. Summary of Results for Powders of Anti-CD4 Antibody Produced by CAN-BD
Run Drying temp. (°C)
Particle size (μm)
Water content (%) Mean 95% less than
A 50 1.4 3.5 2.0
B 25 to 30 1.5 5.5 1.7
C 50 1.5 3.9 1.3
D 50 1.8 4.9 1.5
E 50 1.5 4.0 1.4
Aerodynamic particle size was measured as in Fig. 5. The powders were stored for one to several weeks in a vacuum chamber over calcium
sulfate desiccant before their water content was determined using a methanol extraction method and a Denver Instruments Model 260
Titration Controller with a Model 275KF Coulometric Karl Fischer Titrator
1982 Cape et al.pancreatic lipase as high as 860% upon treatment with
supercritical carbon dioxide, although they treated damp
powders by hourly pressurization and depressurization cy-
cling with supercritical carbon dioxide, while our studies were
by CAN-BD of aqueous solutions, followed by dissolution of
the dried LDH or trypsinogen for enzymatic activity assays.
CAN-BD Case Studies
The CAN-BD process described above was used to
obtain ﬁne dry powders of anti-CD4 antibody, AAT and
trypsinogen. An aqueous solution containing the given
protein with excipient(s) was delivered to one inlet of a low
dead volume mixing tee using an HPLC pump set at a
constant ﬂow rate, typically 0.3 to 0.5 ml/min. Supercritical or
near-critical CO2 (typically at room temperature and
1,200 psi) was delivered to the other inlet of the tee using
an ISCO Model 260D syringe pump. The resulting ﬁne
emulsion of liquid near-critical CO2 and aqueous protein
solution was then rapidly expanded to near atmospheric
pressure through a fused silica capillary tube (9 to 10 cm
length, 74 μm I.D.) into a glass drying chamber (1 to 2.5 l) to
form a very ﬁne aerosol of aqueous droplets. Preheated
nitrogen was passed through the drying chamber at 15 to 30 l/
min to maintain the average temperature at a selected set
point (usually between 25°C and 65°C), thereby drying the
aerosol to form dry particles, which were collected on a ﬁlter
(0.2 or 0.45 μm mixed cellulose ester, 142 mm diameter,
Advantec MFS, Inc., Dublin, CA) located at the exit of the
drying chamber.
Anti-CD4 Antibody
Using the CAN-BD process, we have successfully
produced ﬁne, dry powders of anti-CD4 antibody, a Primat-
ized monoclonal antibody with potential clinical value in
treating rheumatoid arthritis and other diseases. Anti-CD4
antibody was expressed in CHO cells and puriﬁed by several
chromatographic steps to homogeneity. The material was
formulated in a proprietary buffered solution containing
saccharide and surfactant as stabilizing excipients and was
used as provided by Biogen Idec Inc. (San Diego, CA).
Figure 2 (91) is a representative SEM image of particles
produced at 50°C. The particles display dimpled “ping-pong
ball” morphology. Figure 3 is an SEM image of anti-CD4
antibody particles dried at about 30°C and displays the same
morphology, although the dimple effect is somewhat less
pronounced. Such morphology was characteristic of all anti-
CD4 antibody powders that we generated by CAN-BD and
suggests that the particles are hollow, or at least began as
Table VI. Summary of Trypsinogen-Sugar Particles Generated by CAN-BD
Composition by weight percent Aqueous Solution (dry solid) Trehalose Particle size (μm) Sucrose Particle size (μm)
Trypsinogen Sugar
a Mean <95% Mean <95%
1 (100) 0 0.86
b 1.57
b
1 (80) 0.25 (20) 0.86 1.47 0.86 1.57
1 (67) 0.5 (33) 0.89 1.53 0.87 1.47
1 (50) 1 (50) 0.90 1.56 0.87 1.56
1 (33) 2 (67) 0.93 1.75 1.02 1.85
1 (20) 4 (80) 1.02 2.06 1.06 1.93
1 (11) 8 (89) 1.17 2.47 1.33 2.86
0 10 (100) 1.34 2.58 1.43 2.88
aThe sugar used as an excipient was either sucrose or trehalose.
bThese particles contained no sugar, only trypsinogen.
Fig. 9. SEM image of commercial as-received lyophilized trypsinogen.
Fig. 10. SEM image of particles produced by CAN-BD from an
aqueous solution containing 10 mg/ml trypsinogen (average aerody-
namic diameter: 0.86 μm, 95%<1.57 μm).
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which is presented in Fig. 4, lends additional credence to the
suggestion of hollow character by demonstrating that the
particles are less dense in the centers, as seen by the lighter
region in the center of particles.
While the goal of producing dry powders of anti-CD4
antibody by CAN-BD was primarily as an alternative to the
traditional freeze-drying or spray-drying processes, the size
distribution shown in Fig. 5 indicates that these powders are
also suitable for delivery by inhalation. Average aerodynamic
size of the particles was 1.4 μm [squarely centered in the 1 to
3 μm range recommended by Corkery (4)] with 95% of the
particles less than 3.5 μm in diameter. The distribution in
Fig. 5 is representative of all the anti-CD4 antibody powders
generated by CAN-BD. In addition, ﬁnal moisture content of
the powders as determined by Karl Fischer titration was 2%
or less, a value targeted as desirable for stability of dry
formulations of proteins produced by freeze-drying (1).
A concern during the production of dry protein for-
mulations by any process is that of protein aggregation.
Figure 6 shows that the anti-CD4 antibody formulation was
successfully processed by CAN-BD without the irreversible
formation of any aggregates. The starting material and the
rehydrated CAN-BD powder display essentially identical
size-exclusion chromatography (SEC) proﬁles. Protein aggre-
gation due to CAN-BD processing was also not observed by
SEC for any of the other anti-CD4 antibody powders
produced by CAN-BD (data not shown).
Preparation of stable and active anti-CD4 antibody
powders by CAN-BD is demonstrated by the full retention
of biological activity. Table IV shows that the ELISA antigen
binding activity of the reconstituted CAN-BD processed anti-
CD4 antibody powder is statistically no different from that of
the bulk starting solution. The data also demonstrate that in
terms of binding activity retention, CAN-BD processing
performs equally well as lyophilization. It should be noted
that the binding assay was performed on CAN-BD particles
rehydrated after 3 months of storage at room temperature,
indicating that the CAN-BD anti-CD4 antibody powders are
stable upon storage.
The reproducibility of generating anti-CD4 antibody
powders by CAN-BD without signiﬁcant structural perturba-
tion is demonstrated by consistent and comparable secondary
structure of the dried protein, not only for powders generated
under very similar processing conditions, but also for powders
Fig. 11. SEM image of particles produced by CAN-BD from an
aqueous solution containing 10% (w/w) trehalose (average aerody-
namic diameter: 1.34 μm, 95%<2.58 μm).
Fig. 13. SEM image of particles produced by CAN-BD from an
aqueous solution containing 10 mg/ml trypsinogen and 1% (w/w)
trehalose (average aerodynamic diameter: 0.90 μm, 95%<1.56 μm).
Fig. 12. SEM image of particles produced by CAN-BD from an
aqueous solution containing 10 mg/ml trypsinogen and 4% (w/w)
trehalose (average aerodynamic diameter: 1.02 μm, 95%<2.06 μm).
Fig. 14. SEM image of particles produced by CAN-BD from an
aqueous solution containing 5% (w/w) sucrose (average aerodynamic
diameter: 1.45 μm, 95%<2.92 μm).
1984 Cape et al.produced by CAN-BD at different drying temperatures.
Second-derivative IR spectra in the conformationally sensi-
tive amide I region (Fig. 7)( 119–121) demonstrate that the
secondary structure for anti-CD4 antibody powder dried at
50°C is essentially identical (within experimental error) to
that dried at about 30°C. The spectra (not shown) for the
other CAN-BD powders of anti-CD4 antibody also overlay
within experimental error the spectra shown in Fig. 7.I n
addition, Fig. 7 shows that the secondary structure of anti-
CD4 antibody in the dry CAN-BD powders is substantially
the same as that of native anti-CD4 antibody in aqueous
solution prior to CAN-BD processing.
CAN-BD powder generation reproducibility is also
demonstrated by the summary of particles sizes and residual
moisture content presented in Table V. Mean aerodynamic
diameters of the anti-CD4 antibody CAN-BD particle size
distributions were typically 1.5 μm with 95% of the particles
almost invariably ≤ 5 μm. Equilibrium residual moisture
content was in all cases 2% or less.
α1-antitrypsin (AAT)
We have successfully formed ﬁne dry powders of the
enzyme α1-antitrypsin (AAT) by CAN-BD. AAT (Cat. #
A6150) was purchased from Sigma-Aldrich Corp. (St. Louis,
MO, USA) and used without further puriﬁcation. Trehalose
(Cat # T-104-1) was purchased from Pfanstiehl Laboratories,
Inc. (Waukegan, IL, USA). AAT solutions were prepared by
dissolving a known mass of the solid, commercially lyophi-
lized powder in the desired buffer solution.
Figure 8 is a representative SEM image of particles of
AAT generated at 40°C drying temperature from an aqueous
solution containing 2.8% (w/w)A A Ta n d4 . 6 %( w/w)
trehalose in 0.1 M sodium phosphate, at pH 7.0 with 0.1%
(w/w) Tween-20. The resulting dry powder consisted of
particles with an average aerodynamic diameter of 2.2 μm,
while 95% of the particles had a diameter of <5.3 μm. Water
content of the ﬁnal dry powder was 1.8%. AAT processed by
CAN-BD into dry powder retained 98%±2% of its original
activity when reconstituted in water. Biological activity of
AAT was determined using the elastase inhibitory activity
assay described by Travis and Johnson (122).
Particles of AATwere also produced by CAN-BD at 50°C
from an aqueous solution containing 4% (w/w)A A Ta n d4 %
(w/w) trehalose in 0.1 M sodium phosphate, pH 7.0 with 0.01%
(w/w) Tween-20. The resulting dry powder displayed a
qualitative morphology as observed by SEM (data not shown)
that was very similar to that seen in Fig. 8 and consisted of
particles with an average aerodynamic diameter of 1.9 μm
(95% of the particles had a diameter of <5.4 μm). The water
content of the ﬁnal dry powder in this case was also deter-
mined to be 1.8%. As before, AAT in the CAN-BD processed
dry powder retained full activity, displaying 106%±10%
recovery of its original activity when reconstituted in water.
For both dry powder samples, the size-exclusion chro-
matography proﬁles of CAN-BD processed AAT were nearly
identical to the AAT in the original unprocessed sample,
Fig. 15. SEM image of particles produced by CAN-BD from an
aqueous solution containing 10 mg/ml trypsinogen and 4% (w/w)
sucrose (average aerodynamic diameter: 1.06 μm, 95%<1.93 μm).
Fig. 16. SEM image of particles produced by CAN-BD from an
aqueous solution containing 10 mg/ml trypsinogen and 1% (w/w)
sucrose (average aerodynamic diameter: 0.87 μm, 95%<1.56 μm).
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Fig. 17. Apparent activity recovery of trypsinogen stabilized with
trehalose. The trypsinogen concentration in the original aqueous
solution was in all cases 10 mg/ml except for the 50:1 ratio (5 mg/ml
trypsinogen). Enzymatic activity was determined using a previously
established assay (123) with the appropriate modiﬁcations.
1985 Preparation of Active Proteins, Vaccines and Pharmaceuticalsindicating that CAN-BD processing caused no physical
degradation or irreversible aggregation (data not shown).
Trypsinogen
The CAN-BD process was able to generate dry and
stable particles of the model protein trypsinogen in the
appropriate size range for pulmonary drug delivery. Trypsin-
ogen (Cat # LS003649) was obtained from the Worthington
Biochemical Corporation (Lakewood, NJ, USA) and was
used without further puriﬁcation.
The stabilizing effect of two disaccharide sugars, sucrose
and trehalose, on trypsinogen processed by CAN-BD was
investigated. Sucrose (Cat # S-124-1) and trehalose (Cat # T-
104-1) were purchased from Pfanstiehl Laboratories. Each
sugar was combined with the protein in varying ratios of
sugar to protein. Protein concentration in the pre-CAN-BD
solution was kept constant at 10 mg/ml in formulations in
which the sugar concentrations varied from 0%, 0.25%, 0.5%,
1%, 2%, 4%, and 8% (w/w; see Table VI). Another condition
was also tested (protein concentrations and percentages of
sugar refer to concentrations in the pre-CAN-BD solutions):
5 mg/ml trypsinogen with 25% sugar.
The average aerodynamic diameter of the particle was
dependent on the concentration of total dissolved solids
(TDS) in the initial aqueous solution. For concentrations
ranging from 1% to 10% (w/w) TDS, the average aerody-
namic diameters ranged from 0.8 μm to 1.4 μm, respectively.
From Table VI it can be seen that as the TDS increased in the
aqueous solution, the corresponding average particle aerody-
namic diameter in the dry powders (either with trehalose or
sucrose as an excipient) also increased. This dependence of
the particle size upon the initial solution concentration has
also been reported elsewhere (110). An SEM image of the as-
received trypsinogen product is presented in Fig. 9 and shows
it consists of very large ﬂakes. Representative SEM images
and particle size distributions of the CAN-BD processed
trypsinogen formulations show the particles to be in the
appropriate size range for the most effective pulmonary
delivery (See Figs. 11, 12, 13, 14, 15 and 16 and Table VI).
Fig. 10 shows an image of trypsinogen particles, generated
from a 1% (w/w) aqueous solution. It shows that CAN-BD
generated dimpled raisin-like particles with a mean aerody-
namic diameter of 0.86 μm and 95% of particles less than
1.57 μm. Fig. 11 shows an image of trehalose particles, without
any protein, generated from a 10% (w/w) aqueous solution. It
shows spherical particles with a mean aerodynamic diameter of
1.34 μm and that 95% of the particles are less than 2.58 μmi n
diameter. All trypsinogen–trehalose mixtures processed by
CAN-BD showed increasingly dimpled or raisin-like particle
morphology with increasing trypsinogen concentration. Upon
inclusion of 20% or more trypsinogen (mass percent in the
dried solid), the morphologies of the particles were all very
similar, that is, raisin-like (see Figs. 12 and 13). Similar
morphologies were observed for particles generated from
trypsinogen formulations containing sucrose instead of treha-
lose. Figure 14 shows an image of sucrose particles that were
synthesized as spheres. Similar to the formulations containing
trehalose, Figs. 15 and 16 show that trypsinogen–sucrose
particles have raisin-like morphologies upon inclusion of 20%
or more trypsinogen (mass percent in the dried solid).
The presence of the excipients (i.e., sucrose or trehalose)
preserves the activity of the enzyme through the micron-
ization and drying of the CAN-BD process (Fig. 17 shows the
results for trehalose; similar results were obtained for
sucrose) (123). In the absence of a stabilizing sugar, the
activity of the enzyme was only 48% of its original activity
when redissolved in water after CAN-BD. Previous experi-
ments have shown that most of the damage experienced by
the protein occurs during the drying process, after the aerosol
is generated (91). The addition of either sucrose or trehalose
in fractions constituting 80% to 89% (w/w) of the TDS was
able to improve the retained activity of the trypsinogen
processed by CAN-BD to near 100%. We have also
measured the activity of the CAN-BD treated particles that
have been stored in a vacuum chamber for 6 months over
calcium sulfate desiccant. The activity of the particles
remained virtually unchanged, indicating that the CAN-BD
treated powders are stable for at least 6 months when kept
dry at room temperature.
In formulations with very high sugar concentration
(>95% of the TDS), we observed an apparent enzyme activity
greater than 100% of the original. The trypsinogen was used
in formulations as received, with no puriﬁcation attempts
prior to processing to remove any aggregated or denatured
and inactive protein impurities. It is possible that some
reversibly aggregated, denatured protein or improperly
folded molecules were present in the as-received commercial
product. During the CO2-pressurization-depressurization cy-
cling in CAN-BD, such inactive trypsinogen molecules may
have become renatured or refolded to an active conforma-
tion, thus explaining the apparent enhancement of the
originally measured enzyme activity. Similar enhancements
relative to original enzyme activity have been previously
observed in CAN-BD studies with a different enzyme, lactate
dehydrogenase (11,117).
All trypsinogen–sugar formulations studied were ana-
lyzed by size exclusion chromatography (SEC) for the
presence of soluble aggregates. No signiﬁcant agglomeration
of the protein after processing by CAN-BD was observed
(data not shown)
To assist in the protection of the structural integrity of the
protein in the dried state it is important to use excipients that
will be in the amorphous rather than crystalline state (1). Both
sucrose and trehalose are amorphous after processing by
CAN-BD as conﬁrmed by X-ray diffraction (data not shown).
CONCLUSIONS
After surveying the published literature, we conclude
that SCF processes generally, and SCF anti-solvent processes
particularly, have limited application to the preparation of
powders and particles containing active proteins. This is due
to the fact that all these SCF processes, excepting RESS,
require the presence of organic solvents. One notable excep-
tion is the CAN-BD process, which can nebulize aqueous
solutions without the use of an organic solvent, which almost
invariably causes degradation of sensitive biomolecules and
vaccines. CAN-BD (or supercritical-assisted atomization or
effervescent atomization) uses a dense gas (near-critical or
supercritical CO2), not as a solvent or anti-solvent, but as a
tool to facilitate aerosolizing a solution of interest to form
1986 Cape et al.microdroplets and microbubbles, which rapidly dry to pro-
duce microparticles and nanoparticles. CAN-BD has been
successfully applied to a wide range of substances (e.g., small-
molecule pharmaceuticals, protein therapeutics and various
excipients) formulated as aqueous or organic (e.g., methanol,
ethanol, acetone, etc.) solutions. The resulting powders
routinely consist of particles with mean aerodynamic diame-
ter between about 1 to 2 μm, with 95% of the particles usually
less than 3 to 5 μm in diameter, making such powders suitable
for use in dry powder inhalers or in metered dose inhalers. In
addition to these desirable particle size characteristics,
appropriately formulated protein-containing particles can be
readily produced by CAN-BD without process-induced
physical degradation (e.g., protein aggregation) or unaccept-
able loss of biological activity. This has been repeatedly
demonstrated, in previous publications (11,69–75,91,92,101,
105,116,117) with various biologicals (such as the enzymes
lysozyme and lactate dehydrogenase, human IgG antibody,
aluminum hydroxide adjuvanted hepatitis B surface antigen,
and attenuated live virus measles vaccine) and in this
publication with two therapeutically interesting proteins
(anti-CD4 antibody and AAT) and a model enzyme (trypsin-
ogen). Fine dry powders of anti-CD4 antibody or AAT,
produced by CAN-BD from buffered solutions containing
sugars and surfactants as stabilizing excipients, retained full
biological activity upon redissolution with water and no
detectable process-induced aggregation was observed by
size-exclusion chromatography. Enzymatic activity of trypsin-
ogen was essentially fully retained when sucrose or trehalose
was included at 80% or more of the dry powder mass.
Apparent activities greater than 100% of the original as-
received enzyme were reproducibly achieved for trypsinogen
formulations that contained very high sugar content (98–99%
of the dry powder mass). Presumably, these enhanced
activities occur when previously inactive protein molecules
are returned to a native conformation through some as yet
unknown mechanism during the CAN-BD processing (CO2
pressurization, depressurization, and aerosolization and dry-
ing) of trypsinogen in a favorable environment (i.e., high
sugar concentrations). Similar activity enhancement results
have been previously observed for another enzyme, lactate
dehydrogenase (11,117).
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